Belgium has expressed dissatisfaction with the European Union's proposed Critical Medicines Act, which aims to bolster the manufacturing of essential medicines in response to increasing supply chain vulnerabilities.

The initiative is part of a broader EU strategy to reduce dependency on pharmaceutical production concentrated in countries like India and China.

The proposed legislation was developed following extensive discussions regarding the need for a more resilient medicine supply chain, particularly highlighted during the COVID-19 pandemic, which underscored the risks associated with over-reliance on a limited number of manufacturing locations.

Recently, EU health ministers have called for an establishment of funding mechanisms to support the implementation of this bill.

In an open letter, they proposed utilizing resources from the EU's new defense strategy to finance solutions for drug shortages, underscoring the urgency and significance of the healthcare crisis.

The Critical Medicines Act seeks to enhance production capacity within EU member states, thereby ensuring that essential medicines remain available even in times of disruption.

This aims not only to safeguard public health but also to foster autonomy in pharmaceutical manufacturing.

Belgium's reaction to the Act reflects broader concerns regarding its potential efficacy and the pace of its implementation.

Belgian officials have indicated that while they recognize the importance of addressing drug shortages, they believe the proposed measures may not adequately address the immediate challenges facing healthcare systems.

As the EU progresses with the bill, health ministers are assessing various strategies to align resources and legislative frameworks to tackle potential disruptions in medicine supply effectively.

The discussions come amid a global context where countries are increasingly vigilant about their healthcare dependencies and supply chain security.